The health care industry's campaign of fear, uncertainty and doubt

By Wendell Potter

Commentary: health insurers use a host of tactics to erode support for Obamacare.

Reader-approved analysis from Wendell Potter

By Sarah Whitmire

Revisit some of the best analysis from former health insurance exec-turned-whistleblower, Wendell Potter.

OPINION: drug firms say no to rebates, despite billions in new revenue from Part D

By Wendell Potter

Part D brought drug companies billions, but they say the sky is falling

OPINION: Big Pharma's stranglehold on Washington

By Wendell Potter

Pharmaceutical firms are getting their money's worth on Capitol Hill.

Drug lobby gave $750,000 to pro-Hatch nonprofit in Utah's U.S. Senate race

By Michael Beckel

IRS records show drug lobby helped Utah senator, Montana Supreme Court candidate, others.

Analysis — Are seniors paying attention to Paul Ryan's plan for Medicare?

By Wendell Potter

ANALYSIS: Republicans sold seniors a bill of goods on health care reform and Medicare

Tobacco company penalties may signal U.S. crackdown on industry practices overseas

By Traver Riggins and Ricardo Sandoval Palos

A flurry of federal enforcement action targeting payoffs by subsidiaries of two U.S. tobacco companies may signal a broader regulatory assau

The top ten PACs that will miss Chris Dodd

By Aaron Mehta and Josh Israel

When Connecticut Democrat Chris Dodd first ran for the Senate in 1980, his campaign cost only about $1.4 million. But three decades later, r

Excerpts from this story referencing "Bank of America":

"… the top ten PACs that have supported Dodd over his entire Senate career:1. Bank of America at least $165,2992. JPMorgan Chase at least $150,6033. American Bankers As …"

"… d Brokers of America declined to comment for this story. A spokeswoman for Bank of America noted that their PAC is “funded by voluntary contributions by associates …"

How do health care lobby dollars match influence in Congress?

By Adam Clark Estes

Who's really paying for and benefiting from reform?

Commentary: Changing Washington: The hard part

By Bill Buzenberg

The difficulty overcoming the entrenched political tradition of earmarks is just one of many hard realities that will test the Obama Adminis

More big money from pharmaceutical lobby in 2008

By Mary Beth Lombardo

The economy may be sliding, but that hasn’t stemmed the high-rolling habits of Washington’s largest lobby. In 2007, as the Center recently r

A record year for the pharmaceutical lobby in '07

By M. Asif Ismail

Washington's largest lobby racks up another banner year on Capitol Hill

FDA staff travels on drug industry dollars

By Alexander Cohen

Groups tied to FDA-regulated industry paying for agency officials' trips

FDA: A shell of its former self

By M. Asif Ismail

The Food and Drug Administration lacks the power to regulate pharmaceuticals and keep you safe

Surrogates for their agenda

By Alexander Cohen

How the drug industry uses non-profits to push its interests

Drug industry influence timeline

What the pharmaceutical industry has gotten on its political investment

Exporting prices

By M. Asif Ismail

Drug makers' trade group makes the industry's priorities U.S. trade policy

PhRMA's envoys

By M. Asif Ismail

Former ambassador lobbies Canadians on drug imports to U.S.

The state money race

By Derek Willis

Democrats outraised GOP in the states, but have little to show for it

Silent Partners: Special Report

By Derek Willis and Aron Pilhofer

How political non-profits work the system

Lobbying, old-time politics block legislation on human cloning

By M. Asif Ismail

Bush administration articulates no position

Excerpts from this story referencing "Kentucky":

"… ake enactment of oversight legislation even more difficult.A University of Kentucky professor, Panayiotis M. Zavos, said in late January 2001 that he and an I …"

Commentary: How Bush handles McCain will set tone for his presidency

By Charles Lewis

WASHINGTON, January 23, 2001 — Now that George W. Bush has been duly sworn in as the 43rd president of the United States, he immediately fac

Excerpts from this story referencing "Kentucky":

"… d it passed in both 1998 and 1999. However, Majority Leader Trent Lott and Kentucky Republican Mitch McConnell managed to kill it in the Senate when McCain an …"

Montana an unlikely target for out-of-state campaign cash

WASHINGTON, October 25, 2000 — Montana might not seem like the logical setting for a full-scale brawl over a U.S. Senate seat, but with the

Excerpts from this story referencing "U.S. Chamber of Commerce":

"… ton media consultants and lobbyists to push their case on Capitol Hill.The U.S. Chamber of Commerce also ran newspaper ads in the state supporting the legislation – it plan …"

Stealth PACs revealed

By The Center for Public Integrity

February 9, 2000 — The 2000 election cycle promised to be a high-stakes and free-spending election by anyone's measure. The balance of power

Excerpts from this story referencing "The Washington Post":

"… than 50 media outlets nationwide, including U.S. News & World Report, The Washington Post, and The San Francisco Examiner.527 GroupsThe Christian Coalition: Th …"

"… ent on the organizations specific campaign efforts this cycle.According to The Washington Post, Citizens for Better Medicare is abandoning its 527 tax status in part to …"

Chemical industry among big spenders on lobbying this quarter

By Dave Levinthal

New numbers indicate it's still good to be a lobbyist in America.

OPINION: favors for special interests

By Wendell Potter

Insurers, drug companies get what they want from Congress; the public, not so much

Drug lobby donation went to pro-Democratic nonprofit

By Michael Beckel

Half-million-dollar donation from PhRMA went to little-known group that backed Harry Reid.

Heart testing bill signed by Perry required unnecessary tests, critics charge

By Rochelle Sharpe

Medical experts say measure signed by Perry requires unnecessary testing

Pages